Recombinant Humanized Bispecific Monoclonal Antibody MBS301 Clinical Trials

1 actively recruiting trial

Also known as: MBS301

Pipeline

Phase 1: 1

Top Sponsors

Beijing Mabworks Biotech Co., Ltd.1

Indications

HER2-positive Recurrent or Metastatic Malignant Solid Tumor1
Cancer1

Other1 trial

Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.